Jynarque
Ended Awarded Last action
- Contract number
- 36C24622N0566
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $11,414
Award facts
- Contract value 100% obligated
- $11,413.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6850 Miscellaneous Chemical Specialties
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
On March 21, 2022, the Department of Veterans Affairs, through Veterans Integrated Service Network 6, awarded a delivery order valued at $11,413.72 to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan). This firm-fixed price contract, which was completed by April 1, 2022, was issued without a set-aside designation and performed in Pittsburgh, Pennsylvania. Jynarque is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veterans. The award was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), reflecting the established procurement relationship between the VA and Otsuka.
This delivery order represents a task order against Otsuka America Pharmaceutical Inc.'s larger Blanket Purchase Agreement with the VA's National Acquisition Center, valued at approximately $83.3 million and extending through March 26, 2026. The BPA enables VA facilities across multiple Integrated Service Networks to efficiently procure Jynarque for veterans nationwide. Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, maintains a significant Federal Supply Schedule contract exceeding $396 million for pharmaceuticals and hematology-related products, demonstrating its substantial role in supporting the VA's mission to provide specialized pharmaceutical treatments to the veteran population.
Quick answers
Who was awarded contract 36C24622N0566?
36C24622N0566 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on March 21, 2022.
How much is contract 36C24622N0566 worth?
The government has obligated $11,414 on 36C24622N0566.
Is contract 36C24622N0566 an order under another contract?
Yes. 36C24622N0566 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24622N0566 competed?
The extent of competition for 36C24622N0566 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award